




The relative strengths and weaknesses of Lantern Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lantern Pharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 133% points. The greatest weakness of Lantern Pharma Inc is the variable Research and Development, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 282%, being 68% points above the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	25,248
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,331
Liabilities, Non-Current	53
Other Assets	277
Other Compr. Net Income	261
Other Expenses	0
Other Liabilities	0
Other Net Income	1,435
Other Revenues	0
Property and Equipment	47
Research and Development	16,126
Selling, General and Administrative Expense	6,091

Output Variable	Value in 1000 USD
Assets	25,572
Liabilities	4,384
Expenses	22,216
Revenues	0
Stockholders Equity	21,188
Net Income	-20,781
Comprehensive Net Income	-20,650
BaseVar	26,934
ECR before LimitedLiability	171%
Economic Capital Ratio	282%